Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | MTOR | P42345 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228033 | 0.82 | ACHE (0.47) | PIK3CAACHECCNT1CCNA2CDK2 | |
| SCHEMBL28059058 | 0.82 | DYRK1A (0.44) | PIK3CAACHECCNT1CCNA2CDK2 | |
| SCHEMBL5457199 | 0.81 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3R1PIK3CBACHE | |
| SCHEMBL28059059 | 0.81 | MAPK8 (0.47) | PIK3CAACHEKDM4ECCNT1CCNA2 | |
| SCHEMBL16815392 | 0.81 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3R1PIK3CBACHE | |
| SCHEMBL1110254 | 0.80 | PIK3CA (0.54) | PIK3CAPIK3CDPIK3R1PIK3CBACHE | |
| SCHEMBL1600415 | 0.80 | PIK3CA (0.61) | PIK3CAPIK3CDPIK3R1PIK3CBACHE | |
| SCHEMBL3896595 | 0.80 | PIK3CA (0.54) | PIK3CAPIK3CDPIK3R1PIK3CBACHE | |
| SCHEMBL13033008 | 0.80 | KMT2A (0.56) | PIK3CAPIK3CDPIK3R1PIK3CBACHE | |
| SCHEMBL568877 | 0.80 | PIK3CA (0.54) | PIK3CAPIK3CDPIK3R1PIK3CBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089385-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| EP-1505963-B9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2340830-A2 | Hepatitis C Virus Inhibitors | Bristol-Myers Squibb Company (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-1505963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2008057875-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057873-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057871-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007056120-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
| EP-1667980-A1 | 1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028444-A1 | 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | PIK3CA 162/4885PIK3CD 215/4885PIK3R1 250/4885 |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | PIK3CA 278/4885PIK3CD 544/4885PIK3R1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.